IPOs Trimmed

Two biotechs raised $50 million in a pair of IPOs last week, though neither was able to achieve the type of valuation they had hoped for.

First up was Trius Therapeutics Inc. (NASDAQ:TSRX), which limped into the market on Tuesday, selling 10 million shares at $5 in a deal that valued it at $117.8 million. The offering was underwritten by Citigroup; Piper Jaffray; Canaccord; and JMP Securities...